Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.

Article Details

Citation

Copy to clipboard

Goldberg T, Berrios-Colon E

Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.

P T. 2013 Jan;38(1):23-6.

PubMed ID

23599666 [ View in PubMed

]

Abstract

Not Available

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Abiraterone	Cytochrome P450 2C19	Protein	Humans	Unknown	Inhibitor	Details

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Amoxapine Abiraterone	The metabolism of Amoxapine can be decreased when combined with Abiraterone.
Astemizole Abiraterone	The metabolism of Astemizole can be decreased when combined with Abiraterone.
Clomipramine Abiraterone	The metabolism of Clomipramine can be decreased when combined with Abiraterone.
Clonidine Abiraterone	The metabolism of Clonidine can be decreased when combined with Abiraterone.
Dacomitinib Abiraterone	The metabolism of Dacomitinib can be decreased when combined with Abiraterone.